Heron Therapeutics, Inc.
Financials
Valuation Metrics
Heron Therapeutics, Inc.'s Market Cap is $60M. At end of 2025 it was $217M. Ranked #3096 of 3,121 in US market (top 99%), #1439 of 1,463 on NASDAQ (top 98%), #265 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 100%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $60M | US#3,096/3,121 Sec#265/266 |
| Revenue | $151M | US#2,635/3,121 Sec#117/266 |
| Net Income | $-34M | US—/3,121 Sec—/266 |
| Total Assets | $252M | US#2,956/3,121 Sec#229/266 |
| Net Assets | $7M | US#2,915/3,121 Sec#241/266 |
| Employees | 128 | US#2,583/3,121 Sec#161/266 |
| Value | ||
| P/B | 8.65x | US#2,568/3,121 Sec#187/266 |
| P/S | 0.40x | US#235/3,121 Sec#3/266 |
| FCF Yield | -20.31% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROA | -13.50% | US#2,720/3,121 Sec#112/266 |
| Op. Margin | -7.19% | US#2,518/3,121 Sec#91/266 |
| Revenue Growth | 0.99% | US#2,175/3,121 Sec#129/266 |
| Financial Health | ||
| Debt Ratio | 3551.74% | US#2,895/3,121 Sec#240/266 |
| Total Debt | $148M | US#2,335/3,121 Sec#103/266 |
| FCF | $-12M | US#2,387/3,121 Sec#89/266 |
| Cash | $21M | US#2,861/3,121 Sec#257/266 |
| Current Ratio | 2.49x | US#978/3,121 Sec#203/266 |
| Performance | ||
| 1Y Return | -73.91% | US#3,086/3,121 Sec#264/266 |
| 1M Return | 4.92% | US#492/3,121 Sec#54/266 |
| From 52W High | -80.02% | US#3,083/3,121 Sec#261/266 |
| 1Y MDD | -79.81% | US#3,067/3,121 Sec#256/266 |
| Trading | ||
| Volume | 879,818 shares | US#1,504/3,121 Sec#164/266 |
| Trading Value | $279403.00 | US#3,096/3,121 Sec#264/266 |
| Per Share | ||
| EPS | $-0.18 | US—/3,121 Sec—/266 |
| BPS | $0.04 | US#2,810/3,121 Sec#237/266 |
Company Info
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.